Radiation before surgery for cancer that has spread to the brain
Tests giving targeted radiation before surgery to adults with brain metastases.
Key facts
- Who runs it
- University Hospital Ostrava
- Where
- Czechia4 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis
- Status
- Recruiting
- People taking part
- 260 people, planned
- Started
- 1 May 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Neoadjuvant Stereotactic Radiotherapy (NaSRT)
- Postoperative Stereotactic Radiotherapy (SRT)
- Record updated
- 4 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cancer that has spread to the brain. They get stereotactic radiotherapy (precisely aimed radiation) in several sessions before surgery to remove the brain tumour.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Brain metastases seen on MRI from a cancer confirmed by tissue testing. The main brain tumour must be planned for surgical removal and be between 1 cm (0.4 in) and 7 cm (2.8 in) at its longest. Any other spread must be treatable with high-dose stereotactic radiotherapy. Karnofsky Performance Status (a score of daily functioning) of 60 or more.
- Earlier treatment
- Cannot have had whole-brain radiotherapy (WBRT). Cannot have had stereotactic radiotherapy to the main brain tumour before.
Main reasons for not taking part
- Confirmed blood cancer
- Small-cell (lung) carcinoma
- Very sudden, severe condition that needs brain surgery right away
- Pregnancy
- Surgery to remove the main brain tumour not possible within 7 days after the radiotherapy
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age ≥ 18 years
- Karnofsky Performance Status ≥ 60
- Histologically verified primary cancer disease
- MRI findings indicating BM
- Target BM indicated for surgical resection and any other metastases suitable for radical SRT
- Target BM between 1 cm and 7 cm at the longest diameter on T1 post-contrast MR imaging
Who cannot take part
- Inability to perform surgical resection of the target BM within 7 days after NaSRT
- Peracute condition requiring immediate neurosurgical intervention
- History of whole-brain radiotherapy (WBRT)
- History of stereotactic radiotherapy to a target brain metastasis
- Confirmed hematological malignity
- Small-cell (lung) carcinoma
- Pregnancy
This trial is currently available in Czechia.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.
The 2 groups in the trial
- Neoadjuvant NaSRT - prospectiveTreatment being tested
Patients undergoing neoadjuvant NaSRT will be enrolled prospectively in this study arm.
Treatment: Neoadjuvant Stereotactic Radiotherapy (NaSRT)
- Postoperative SRT - retrospectiveExisting treatment, for comparison
Patients who underwent postoperative SRT in the past will be analyzed retrospectively in this study arm.
Treatment: Postoperative Stereotactic Radiotherapy (SRT)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis - Prospective Trial NeoSTROBE
- Plain-language title
- Radiation before surgery for cancer that has spread to the brainGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 4 May 2025